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Background: Dysfunction of the glycine transporter 1 (GlyT1) has been suggested to be involved in psychiatric
disorders such as schizophrenia. GlyT1 inhibitors have therefore been considered to have antipsychotic therapeutic
potential. Positron emission tomography (PET) imaging probes for GlyT1 are, consequently, expected to be useful
for investigating the mechanism of such disease conditions and for measuring occupancy of GlyT1 inhibitors in vivo.
The aim of this study was to assess the potential of 2-chloro N-[(S)-{(S)-1-[11 C]methylpiperidin-2-yl} (phenyl)methyl]
3-trifluoromethyl-benzamide ([11 C]N-methyl-SSR504734) as a PET imaging agent for GlyT1.
Methods: [11 C]N-methyl-SSR504734 was synthesized by N-[11 C]methylation of SSR504734 via [11 C]CH3OTf. In vitro
brain distribution of [11 C]N-methyl-SSR504734 was tested in whole-hemisphere autoradiography (ARG) on human
brain slices. Initial PET studies were performed using a cynomolgus monkey at baseline and after pretreatment with
0.1 to 1.5 mg/kg of SSR504734. Then, PET studies using rhesus monkeys were performed with arterial blood
sampling at baseline and after pretreatment with 1.5 to 4.5 mg/kg SSR504734. Distribution volumes (VT) were
calculated with a two-tissue compartment model, and GlyT1 occupancy by SSR504734 was estimated using a
Lassen plot approach.
Results: [11 C]N-methyl-SSR504734 was successfully synthesized in moderate radiochemical yield and high specific
radioactivity. In the ARG experiments, [11 C]N-methyl-SSR504734 showed specific binding in the white matter and pons. In
the initial PET experiments in a cynomolgus monkey, [11 C]N-methyl-SSR504734 showed high brain uptake and consistent
distribution with previously reported GlyT1 expression in vivo (thalamus, brainstem> cerebellum> cortical regions).
However, the brain uptake increased after pretreatment with SSR504734. Further PET studies in rhesus monkeys showed a
similar increase of brain uptake after pretreatment with SSR504734. However, the VT of [
11 C]N-methyl-SSR504734 was
found to decrease after pretreatment of SSR504734 in a dose-dependent manner. GlyT1 occupancy was calculated to be
45% and 73% at 1.5 and 4.5 mg/kg of SSR504734, respectively.
Conclusions: [11 C]N-methyl-SSR504734 is demonstrated to be a promising PET radioligand for GlyT1 in nonhuman
primates. The present results warrant further PET studies in human subjects.
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Glycine is a neurotransmitter of the inhibitory glycine
receptors (GlyRs) but also serves as an essential co-
agonist of the excitatory N-methyl-D-aspartate (NMDA)
receptors [1,2]. It is known that the extracellular glycine
concentration is modulated by two glycine transporters
(GlyT1 and GlyT2) [3]. It has been suggested that GlyT2
is mainly implicated in the control of inhibitory neuro-
transmission via GlyRs, whereas GlyT1 is considered to
regulate the glycine level in both inhibitory neuron and
excitatory neurons [4-8].
It has been indicated that NMDA receptor dysfunction
may be related to various disorders such as schizophre-
nia, Parkinson's Disease, and Alzheimer's Disease [9-11].
Schizophrenia has been hypothesized to be related to the
hypofunction of NMDA receptors. Direct NMDA recep-
tor agonists would cause severe side effects. Targeting
the glycine site of the NMDA receptors has been sug-
gested to be a promising therapeutic strategy through
the facilitation of NMDA receptor functions [12-14].
Indeed, it was reported that enhancement of glycine
concentration in the synaptic cleft by GlyT1 inhibitors,
such as RG1678 (Figure 1), was efficacious in the treat-
ment of the negative and cognitive symptoms of schizo-
phrenia [11,15,16]. In addition, GlyT1 inhibitors could
be potential therapeutic agents for various disorders
associated with inhibitory neurotransmission (e.g., de-
pression and neuropathic pain) [17,18].
Positron emission tomography (PET) is considered as
one of the most useful imaging methods for noninvasive
visualization of target proteins. Development of PET
radioligands for GlyT1 is thus considered useful for
obtaining information about various psychiatric diseases
and occupancy of GlyT1 inhibitors in vivo. Several novel
PET radioligands with high affinity to GlyT1 were
reported recently. Among these radioligands, [11 C]
GSK931145 and [18 F]MK-6577 (Figure 2) showed good
brain uptake, good accumulation in GlyT1-rich regions,
and significant blocking by GlyT1 ligands in the brain of
pigs, rhesus monkeys, and humans [19-21].
The N-[Phenyl (piperidin-2-yl) methyl]benzamide deriva-
tive SSR504734 (Figure 1) is a selective and competitiveFigure 1 Chemical structure of GlyT1 inhibitors.inhibitor of GlyT-1 [22]. Since SSR504734 has moderate
lipophilicity and a molecular weight of 397, SSR504734 may
be a useful lead compound for the development of PET
radioligands. Indeed, SSR504734-related radioligands such
as [11C]SA1 showed high brain uptake and a consistent ac-
cumulation with the GlyT1 distribution in the mouse and
monkey brain [23]. More recently, we developed [125I]2-
iodo N-[(S)-{(S)-1-methylpiperidin-2-yl} (phenyl)methyl]3-
trifluoromethyl-benzamide ([125I]IMPB) as a promising
SPECT ligand candidate [24].
It was previously reported that N-methyl-SSR504734
has high affinity for GlyT1 (1.6 nM) [25] and a potent
GlyT1 inhibitory activity (IC50 = 2.4 nM) [24]. The same
structure with [11 C]N-methyl-SSR504734 was reported
recently [23]. In vivo [11 C]N-methyl-SSR504734 showed
high brain uptake; however, PET evaluation using non-
human primates were not so far reported in the litera-
ture [23]. In this study, we aimed to synthesize [11 C]N-
methyl-SSR504734 and evaluate its distribution by
in vitro autoradiography in human brain slices and by
in vivo PET studies in monkeys.
Methods
General
SSR504734 and N-methyl-SSR504734 were synthesized
according to the literature [25,26]. All other chemicals
were obtained from commercial sources, were of ana-
lytical grade, and were used as received. Purification
of [11 C]N-methyl-SSR504734 was performed by a
high-performance liquid chromatography (HPLC) sys-
tem consisting of a Merck-Hitachi absorbance de-
tector (λ = 254 nm; VWR International, Stockholm,
Sweden) in series with a GM tube (Carroll-Ramsey,
Berkely, CA) for radioactivity detection. The purified
[11 C]N-methyl-SSR504734 was analyzed by a HPLC
system consisting of a Merck-Hitachi L-7100 Pump,
L-7400 UV detector, and GM tube for radioactivity
detection (VWR international). The radiometabolism of
each product in monkey plasma was assessed with HPLC
on a system that contained a Merck-Hitachi D-7000 inter-
face module, L-7100 pump and an L-7400 absorbance de-
tector (λ=254 nm; Merck-Hitachi, Tokyo, Japan), and an
Figure 2 Chemical structure of PET radioligands for GlyT1.
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USA) equipped with a μ-Bondapack-C18 column
(300× 7.8 mm, 10 μm; Waters, Milford, MA, USA) in
series with a 150TR radiodetector (Packard Radiomatic,
PerkinElmer, Waltham, MA, USA) equipped with a PET
flow cell (550 μl).Preparation of [11 C]N-methyl-SSR504734
Ultrahigh specific activity of [11C]CH3I and [
11C]CH3OTf
was prepared from [11C]CH4 as described previously [27].
In brief, [11C]CH4 was obtained via
14N(p,a)11C reaction
on nitrogen containing 10% hydrogen with 16 MeV pro-
tons. [11C]CH4 reacted with iodine at high temperature in
a heated quartz column and converted to [11C]CH3I.
[11C]CH3OTf was prepared by carrying [
11C]CH3I vapor
through a heated glass column containing silver triflate-
impregnated graphitized carbon. The [11C]CH3I or [
11C]
CH3OTf was trapped in a vessel containing SSR504734
(0.6 mg, 1.51 μmol), organic solvent (DMF, acetone or
CH3CN; 400 μl), and base (NaH or NaOH; 5 μmol). After
3 min, the radioactive reaction mixture was purified by an
HPLC (column, ACE5 C18-HL, 250× 10 mm; mobile
phase, CH3CN: 0.1 M NH4HCO2 in H2O=45:55; flow
rate, 6.0 ml/min). The solvents in the collected product
fraction were evaporated at 70°C, and the final product
was formulated in phosphate buffered saline (PBS; pH=
7.4). The purity of the product was analyzed by an HPLC
(column, μ-Bondapak C18 10 μm 125 Å 7.8× 300 mm;
mobile phase, CH3CN: 0.1% TFA in H2O=30:70; flowrate, 2.0 ml/min) and identified by co-injection of refer-
ence N-methyl-SSR504734.In vitro autoradiography
Human brains without pathology were obtained from
the National Institute of Forensic Medicine, Karo-
linska Institutet (Stockholm, Sweden) as well as from
the Department of Forensic and Insurance Medicine,
Semmelweis University, Budapest. After the removal
of the brains (6- and 11-h post mortem times), they
were kept at −85°C until sectioning; after which, the
whole hemisphere brain slices were kept at −25°C
until the autoradiographic procedures. Ethical per-
missions were obtained from the relevant research
ethics committee of the respective institutions. The
sectioning of the brains and the autoradiography
experiments were performed at the Department of
Clinical Neuroscience, Karolinska Institutet. The cryo-
sectioning took place on a Leica cryomacrocut system
(San Marcos, CA, USA) [28,29]. Horizontal sections
(100 μm thick, containing cerebral cortex, white matter,
cerebellum, and pons) and coronal sections (100 μm thick,
containing cerebral cortex, white matter, putamen, and
caudate nucleus) were used. The sections were incubated
in binding buffer (120 mM NaCl, 2 mM KCl, 1 mM
MgCl2, 1 mM CaCl2, and 50 mM Tris–HCl, pH 7.5) con-
taining [11C]N-methyl-SSR504734 (40 MBq) at 25 °C for
30 min. To determine the nonspecific binding, un-
labelled N-methyl-SSR504734 (10 μM) was included in
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tions. For comparison with other GlyT1 radioligands,
blocking was also made with SSR504734 (10 μM).
The slices were rinsed thrice for 3 min each with cold
(5°C) washing buffer (120 mM NaCl, 50 mM Tris–
HCl, pH= 7.5) and subsequently dipped into cold
water. The slides were then placed on an imaging
plate (Fujifilm Plate BAS-TR2025, Fujifilm, Tokyo,
Japan) for 20 min. The plates were developed, and the
resulting images were processed in a Fujifilm BAS-
5000 phosphorimager (Fujifilm, Tokyo, Japan). Ali-
quots (20 μl) of the incubation solution were spotted
onto polyethylene-backed absorbent paper (Bench-
Guard™, Lennox, Dublin, Ireland), allowed to dry,
scanned, and digitized in the phosphorimager parallel
with the tissue scans. The autoradiography (ARG) sig-
nal's optical density was measured using Multi Gauge
3.2 image analysis software (Fujifilm, Tokyo, Japan).
PET studies in monkeys
PET measurements were performed using a high-
resolution research tomograph (CTI/Siemens Molecu-
lar Imaging, Knoxville, TN, USA) with an in-plane
resolution less than 1.5 mm FWHM in the center of
the FOV [30]. PET data were acquired by list mode.
The data were reconstructed with a series of frames
(5 × 1 min, 5 × 3 min, 5 × 6 min, and 13 × 10 min)
using the Ordinary Poisson-3D-Ordered Subset Ex-
pectation Maximization (OP03D-OSEM) algorithm
with 10 iterations and 16 subsets including modeling
of the points spread function. Image reconstruction
was performed on a quad-core PC running a fast re-
construction algorithm [31].
One female cynomogus monkey (4,900 and 5,200 g at
different PET days) and two female rhesus monkeys
(5,550 and 5,550 g) were used in this study. The study
was approved by the Animal Ethics Committee of the
Swedish Animal Welfare Agency (Dnr 145/08 and 386/
09) and was performed according to the ‘Guidelines for
Planning, Conducting and Documenting Experimental
Research’ (Dnr 4820/06-600) of the Karolinska Institutet
as well as the ‘1996 Guide for the Care and Use of
Laboratory Animals’.
Anesthesia was induced by intramuscular injection of
ketamine hydrochloride (60 mg) and maintained by the
administration of a mixture of sevoflurane, O2, and med-
ical air after endotracheal intubation. The head was
immobilized with a fixation device. Body temperature
was maintained by Bair Hugger Model 505 (Arizant
Healthcare, MN, USA) and monitored by an esophageal
thermometer. ECG, heart rate, respiratory rate, and oxy-
gen saturation were continuously monitored throughout
the experiments. Blood pressure was monitored every
5 min.Magnetic resonance images (MRIs) of each monkey
brain were previously obtained using a 1.5 T General
Electrics Signa system (GE, Milwaukee, WI, USA). PET
measurements consisted of two parts, as follows.
PET measurements using a cynomolgus monkey
PET measurements were performed for 123 min imme-
diately after intravenous (i.v.) injection of radioligand at
baseline and after pretreatment with SSR504734.
SSR504734 was administered over 15 min, starting
30 min before the radioligand injection. PET measure-
ments were performed on two separate days at a 6-week
interval. One baseline PET measurement and one PET
measurement after pretreatment with 0.1 mg/kg of
SSR504734 were performed on the first day. One base-
line PET measurement and two PET measurements after
pretreatment with 0.5 and 1.5 mg/kg of SSR504734 were
performed on the second day.
During each PET measurement, venous blood samples
were taken from a femoral vein for the measurement of
[11 C] N-methyl-SSR504734 protein binding at 5 min be-
fore the radioligand injection and for metabolite analysis
of [11 C]N-methyl-SSR504734 at 4,15, 30, 60, 90, and
120 min after the radioligand injection.
PET measurements using rhesus monkeys
PET measurements were performed for 123 min imme-
diately after i.v. injection of radioligand at baseline and
after pretreatment with SSR504734. SSR504734 was
administered over 15 min, starting 30 min before the
radioligand injection. PET measurements were per-
formed on two separate days with two monkeys. One
baseline PET measurement and one PET measurement
after pretreatment with 1.5 mg/kg of SSR504734 were
performed on one monkey. One baseline PET measure-
ment and one PET measurement after pretreatment with
4.5 mg/kg were performed on the other monkey.
During each PET measurement, arterial blood was col-
lected continuously for 3 min using an automated blood-
sampling system at a speed of 3.0 mL/min (Allog AB,
Molndal, Sweden). Blood samples (1.0 to 2.5 mL) were
drawn at 4, 15, 30, 60, 90, and 120 min after the radioli-
gand injection for blood and plasma radioactivity and
metabolite correction. One arterial blood sample (2.0 ml)
was taken 5 min before the radioligand injection for the
measurement of [11 C]N-methyl-SSR504734 protein
binding.
Metabolite analysis
From the obtained blood samples, plasma was
obtained after centrifugation at 2,000 × g for 2 to
4 min and was mixed with 1.4 times the volume of
acetonitrile. The supernatant acetonitrile-plasma mix-
ture obtained after centrifugation at 2,000 × g for 2 to
Table 1 Synthetic condition for preparation of [11 C]N-methyl-SSR504734
Entry [11 C] methylating
agent
Base Solvent Temperature Time (min) Yield (%)
1 [11 C]CH3I NaH DMF r.t. 5 0
2 [11 C]CH3I NaOH DMF r.t. 5 0
3 [11 C]CH3I NaOH DMF 80 °C 5 0
4 [11 C]CH3OTf NaOH Acetone r.t. 1 25
5 [11 C]CH3OTf NaOH CH3CN r.t. 1 36 to approximately 42
DMF, dimethylformamide; r.t., room temperature.
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HPLC analysis was performed on a Waters μ-Bondapak-C
18 column (300×7.8 mm, 10 μm) by gradient elution using
(a) ammonium formate (100 mM) and (b) acetonitrile at
6.0 mL/min.
Measurement of protein binding
Monkey plasma (500 μL), or PBS (500 μL) as a con-
trol, was mixed with [11 C]N-methyl-SSR504734 solu-
tion (50 μL, approximately 1 MBq) and incubated at
room temperature for 10 min. Samples (20 μL) from
each incubation mixture were measured with a well
counter. After the incubation, 200-μL portions of the
incubation mixtures were pipetted into ultrafiltration
tubes (Millipore Centrifree YM-30, Merck Millipore,
Billerica, MA, USA) and centrifuged for 15 min at
1,500 × g. Samples (20 μL) from each filtrate were
pipetted for counting. The results were corrected for
the membrane binding as measured with the control
samples.
Data analysis
Regions of interest (ROI) for the thalamus, cerebel-
lum, caudate, putamen, frontal cortex, temporal cor-
tex, anterior cingulate cortex, pons, white matter,
and the whole-brain contour were delineated on
PET/MRI co-registered brain images for each mon-
key. Co-registrations and ROI delineations were per-
formed using PMOD 3.0 (Pixel-Wise Modeling
Computer Software, PMOD Group, Zurich, Switzer-
land). PET data were analyzed using several para-
meters such as percent injected dose (%ID) andScheme 1 Radiosynthesis of [11 C]N-methyl-SSR504734.percent standard uptake value (%SUV), where
%ID ¼ total radioactivity in the whole brainðMBqÞ
injected radioactivityðMBqÞ
 100
%SUV ¼ radioactivity ðMBq=ccÞ
injected radioactivity ðMBqÞ
 body weight gð Þ  100:
In the PET measurements using rhesus monkeys,
the total distribution volume (VT) was calculated by
a two-tissue compartment model as well.
GlyT1 occupancy was estimated by applying Lassen
plot approach [32], which can determine nondisplace-
able distribution volume (VND) and occupancy using
VT values at baseline and after pretreatment. Seven
regions (the pons, cerebellum, putamen, frontal cor-
tex, caudate, anterior cingulate cortex, and temporal
cortex) were used for the plot.
Results
Radiochemistry
When [11 C]CH3I was applied as a methylating agent
and NaH or NaOH as a base, the desired [11 C]N-me-
thyl-SSR504734 was not obtained in significant yield.
On the other hand, in the case where [11 C]CH3OTf
was used in the reaction instead of [11 C]CH3I, [
11 C]
N-methyl-SSR504734 was successfully synthesized. The
highest radiochemical yield (36% to 42%, decay cor-
rected from [11 C]CH3OTf) was achieved by using
NaOH as a base and CH3CN as a solvent (Table 1 and
Scheme 1). Specific activity of the ligand was calculated
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the synthesis of [11C]N-methyl-SSR504734 was com-
pleted. The ultrahigh specific activity of the radioligand
was consistent with our previous results by using [11C]
CH4 as a starting precursor [27].Figure 3 In vitro postmortem autoradiography study of human brain.
and horizontal whole-hemisphere (panels D, E, and F; 100-mm thickness) c
SSR504734 under baseline (panels A and D), blocked by non-radioactive N-
(10 μM; panels C and F) conditions. The quantified values of [11 C]N-methyl
temporal cortex; PUT, putamen; CAU, caudate nucleus; CB, cerebellum; WMIn vitro ARG of human brain slices
In the postmortem autoradiography study in vitro, [11 C]
N-methyl-SSR504734 showed a rather homogenous ac-
cumulation in the human brain slices including the tem-
poral cortex, white matter, caudate nucleus, putamen,Autoradiogram from coronal (panels A, B, and C; 100-mm thickness)
ryosections of the human brain incubated with [11 C]N-methyl-
methyl-SSR504734 (10 μM; panels B and E), and blocked by SSR504734
-SSR504734 (C) were expressed as (PSL-BG)/mm2 (panel G). TC,
, white matter.
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[11 C]N-methyl-SSR504734 binding by non-radioactive
N-methyl-SSR504734 and SSR504734 was prominent in
the white matter and pons, but in other regions, the de-
gree of the reduction was small (Figure 3).
PET measurements using a cynomolgus monkey
The injected radioactivity was 144.4 ± 16.5 MBq. Specific
radioactivity was higher than 234 GBq/μmol at the time
of injection. The corresponding injected mass was less
than 0.3 μg.
The summation images are shown in Figure 4. In the
baseline PET measurements (N= 2), time-activity curves
(TACs) of [11 C]N-methyl-SSR504734 in whole brain
reached peak (2.8%ID to 3.1%ID) at 24 min, followed by
a moderate decline (Figure 5A). The rank order of re-
gional brain uptake was as follows: thalamus> pons>
cerebellum ≒ putamen> cortical regions>white matter
(Figures 4A and 5B), which was basically consistent
with in vivo regional brain uptake with other
PET radioligands [19-21]. The radioactivity level of
[11 C]N-methyl-SSR504734 was increased in all regions
after pretreatment with SSR504734 in a dose-dependent
manner (Figures 4B,C and 5C,D).Figure 4 PET images of a cynomolgus monkey. PET images in the trans
cynomolgus monkey, which were acquired from 9 to 123 min after intrave
0.5 mg/kg of pretreatment (B) and 1.5 mg/kg of pretreatment (C) conditionThe parent fraction of [11 C]N-methyl-SSR504734 in
the plasma was reduced during PET measurements.
The metabolite rate was similar during baseline and
pretreatment conditions with SSR504734 (Figure 6A).
Radiochromatograms showed that more hydrophilic
metabolites of [11 C]N-methyl-SSR504734 only were
detected in the plasma (Figure 6B,C). Protein binding
of [11 C]N-methyl-SSR504734 was 87% to 91% at base-
line and after pretreatment.
PET measurements using rhesus monkeys
The injected radioactivity was 170.0 ± 2.4 MBq. Specific
radioactivity was higher than 353 GBq/μmol at the time
of injection. The injected mass was less than 0.2 μg.
In the baseline PET measurements (N= 2), TACs of
[11 C]N-methyl-SSR504734 in the whole brain reached
peak (3.2%ID, 172%SUV to 188%SUV) at 16.5 to 42 min.
The rank order of regional brain uptake was as follows:
thalamus> pons> putamen> frontal cortex≒temporal
cortex> cerebellum>>white matter, as shown in
Figures 7A and 8A. The brain distribution of [11C]N-
methyl-SSR504734 was similar to that of the cynomol-
gus monkey. Likewise, pretreatment with SSR504734
(1.5 and 4.5 mg/kg) caused increase of [11C]N-methyl-axial (left), the sagittal (middle), and the coronal (right) slices of the
nous injection with [11 C]N-methyl-SSR504734 under baseline (A),
s, and the corresponding MRI-T1 image (D).
Figure 5 Time-activity curves of brain radioactivity after intravenous injection of [11 C]N-methyl-SSR504734 in a cynomolgus monkey.
At baseline and pretreatment conditions (0.5 or 1.5 mg/kg of SSR504734). Whole brain uptake was expressed as percent injected dose (%ID) (A).
Regional brain uptake was expressed as percent standard uptake value (%SUV) under baseline (B), pretreatment of SSR504734 (0.5 mg/kg) (C), and
pretreatment of SSR504734 (1.5 mg/kg) conditions (D). Black square, thalamus; white circle, pons; black triangle, cerebellum; white diamond,
putamen; asterisk, frontal cortex; cross, white matter; black circle, caudate; white square, anterior cingulate cortex; white triangle, temporal cortex.
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8B) and considerable rise of the AUC of the arterial in-
put function both at early and late phases (Figure 8C)
in the PET studies of rhesus monkey 2. VT values in
the brain regions of the rhesus monkeys analyzed by
2TC were shown in Table 2. VT could not be
obtained robustly for the white matter. In the baseline
PET measurement of rhesus monkey 1, VT in GlyT1-rich
regions such as the thalamus and pons were at a high
level (31.0 to 35.2), whereas comparable VT values were
observed in other regions (23.1 to 28.6). After pretreat-
ment of SSR504734 (1.5 and 4.5 mg/kg), VT decreased
approximately 20% and 33% reduction of VT values in
the whole brain as shown in Table 2.
Using Lassen plot, a linear fitting to the data points
from seven brain regions was obtained for the dose of
1.5 and 4.5 mg/kg of SSR504734 (Figure 9A,B). Targetoccupancy was calculated to be 45.2% and 74.3% at 1.5
and 4.5 mg of SSR504734, respectively (Figure 9C).
The estimated VND values from the graphical analysis in
Figure 9A,B were 16.5 and 7.5, respectively. Percentage of
VND in VT was 52% to 66% and 39% to 56% at 1.5- and
4.5-mg doses of SSR504734, respectively (Table 3).
Discussion
In the present study, [11 C]N-methyl-SSR504734 was
demonstrated to be a promising PET radioligand to
measure GlyT1 occupancy in nonhuman primates. [11 C]
N-methyl-SSR504734 was synthesized successfully using
[11 C]CH3OTf with moderate radiochemical yield and
ultrahigh specific radioactivity compared with previously
reported GlyT1 imaging [19,20,23].
In the in vitro ARG studies of human brain slices,
[11 C]N-methyl-SSR504734 showed specific binding in
Figure 6 Fraction of [11 C]N-methyl-SSR504734 in the plasma during PET measurements. Percentage of unmetabolized
[11 C]N-methyl-SSR504734 in the plasma of a cynomolgus monkey at baseline and pretreatment conditions (0.5 or 1.5 mg/kg of SSR504734) (A).
HPLC analysis of plasma samples at 4 (C) and 90 min (D) after injection of [11 C]N-methyl-SSR504734 at baseline.
Figure 7 PET images of rhesus monkey 2. PET images in the transaxial (left), the sagittal (middle), and the coronal (right) slices of rhesus
monkey 2 acquired from 9 to 123 min after intravenous injection with [11 C]N-methyl-SSR504734 at the baseline (A) and 4.5 mg/kg of
pretreatment (B conditions, and the corresponding MRI-T1 image (C).
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Figure 8 Time-activity curves of brain radioactivity after intravenous injection of [11 C]N-methyl-SSR504734 in rhesus monkey 2. (A) %
SUV in brain regions at baseline condition. (B) %SUV in brain regions at pretreatment conditions (4.5 mg/kg of SSR5047). Black square, thalamus;
white circle, pons; black triangle, cerebellum; white diamond, putamen; asterisk, frontal cortex; cross, white matter; black circle, caudate; white
square, anterior cingulate cortex; white triangle, temporal cortex. (C) Time-activity curve (%SUV) of metabolite-corrected radioactivity in the plasma
under baseline condition and pretreatment (4.5 mg/kg of SSR504734) condition.
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However, as only small decrease of [11 C]N-methyl-
SSR504734 binding was detected, nonspecific binding
was expected to be high in all brain regions (Figure 3).
Previously, [125I]IMPB, which is a [11 C]N-methyl-
SSR504734 analog, showed excellent high specific bind-
ing to rat brain slices under in vitro ARG studies. In
addition, both IMPB and N-methyl-SSR504734 showed
very high inhibitory activity against the human GlyT1
(IMPB, IC50 = 2.4 nM; N-methyl-SSR504734, IC50 = 7.5
nM) as determined in a [3H]glycine uptake assay usingTable 2 Total distribution volume (VT) in brain regions of the
Animal Parameter THA Pons
Rhesus monkey 1 VT (baseline) 31.0 35.2
VT (Blocking (1.5 mg/kg)) 29.6 26.8
% decrease of VT
a 4.5 23.9
Rhesus monkey 2 VT (baseline) 15.7 16.9
VT (Blocking (4.5 mg/kg)) 11.9 10.9
% decrease of VT
a 24.2 35.5
aPercent decrease of values from baseline study to blocking study. ACC, anterior cin
TC, temporal cortex; THA, thalamus; WB, whole brain.JAR cells [24]. Therefore, it was suggested that this series
of compounds can bind to both rodent and human
GlyT1. The present human ARG results seemed not to
be in line with the previous report [24]. Several factors
such as species differences and condition of the ARG
slices should be taken into consideration.
In PET studies using cynomolgus and rhesus monkeys,
[11 C]N-methyl-SSR504734 showed high brain uptake
and a regional brain distribution consistent with other
GlyT1 PET ligands [19-21]. The low 11 C radioactivity in
the white matter, where GlyT1 binding was reported torhesus monkeys analyzed by 2TC model
CB CAU PUT FC ACC TC WB
23.7 26.2 26.7 25.2 28.6 25.6 23.1
20.4 22.0 22.8 20.6 22.5 21.8 18.6
13.9 16.0 14.6 18.3 21.3 14.8 19.5
12.8 17.0 15.8 14.3 15.5 12.3 12.6
9.0 9.2 10.1 8.6 9.0 8.9 8.5
29.7 45.9 36.1 39.9 41.9 27.6 32.5
gulate cortex; CAU, caudate; CB, cerebellum; FC, frontal cortex; PUT, putamen;
Figure 9 Lassen plot analysis applied to PET occupancy studies. Data were taken from [11 C]N-methyl-SSR504734 studies in the rhesus
monkey brain at baseline and after administration of SSR504734 at doses of 1.5 mg/kg in rhesus monkey 1 (A) and 4.5 mg/kg in rhesus monkey 2
(B). Thalamus (white diamond) was not included for Lassen plot. (C) Relationship between GlyT1 occupancy (in percent) and dose of SSR504734.
The relationship between GlyT1 occupancy (in percent) and dose of SSR504734 was expressed by the equation: Occupancy %ð Þ ¼ Omax  CpCpþKd,
where Omax is the assumed maximal occupancy (i.e., 100%), and Cp is the dose at which occupancy becomes 50%. Kd was estimated to be
1.7 mg/kg.
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http://www.ejnmmires.com/content/2/1/37be high in in vitro ARG studies, was consistent with our
previous ex vivo studies of [125I]IMPB [24] and previous
PET studies with other GlyT1 ligands [19-21]. Compared
with in vitro ARG results, low uptake in the white matter
might be related to low blood flow in the white matter
[33,34].Table 3 Percentage of VND in total distribution volume in rhe
Study Parameter Pons
Baseline + blocking (1.5 mg/kg) VT 31
VND 16.5
% of VND in VT 66
Baseline + blocking (4.5 mg/kg) VT 16.9
VND 7.5
% of VND in VT 56
ACC, anterior cingulate cortex; CAU, caudate; CB, cerebellum; FC, frontal cortex; PUT,
distribution volume.VT values of white matter could not be obtained reli-
ably with the 2TC model. Although several other quanti-
tative methods such as Logan plot were investigated,
they did not work well (data not shown). This unreliable
estimation of VT might be related in part to time-activity
curves in the white matter being relatively noisy due tosus monkeys
CB CAU PUT FC ACC TC
35.2 23.7 26.2 26.7 25.2 28.6
16.5 16.5 16.5 16.5 16.5 16.5
50 55 55 52 59 54
12.8 17 15.8 14.3 15.5 12.3
7.5 7.5 7.5 7.5 7.5 7.5
42 56 53 48 52 39
putamen; TC, temporal cortex; VND, nondisplaceable distribution; VT, volume
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http://www.ejnmmires.com/content/2/1/37potential spillover from the cortex and, in part, to [11 C]
N-methyl-SSR504734 kinetics being slower in the white
matter than in other brain regions.
Although over 70% of [11 C]N-methyl-SSR504734
was metabolized within 90 min after injection of
[11 C]N-methyl-SSR504734, only higher hydrophilic frac-
tion was observed (Figure 6B,C). Because these metabo-
lites of [11 C]N-methyl-SSR504734 are unlikely to
penetrate the blood brain barrier, they are expected to
have little influence on the in vivo brain distribution
pattern of [11 C]N-methyl-SSR504734.
The radioactivity concentration in the brain increased
after pretreatment with SSR504734 in both the cyno-
molgus and rhesus monkeys. [11 C]SA1, which is a struc-
turally analogous compound of [11 C]N-methyl-
SSR504734, has been reported to show similar increase
in brain uptake after pretreatment with SSR504734 in
rhesus monkeys [23]. [11 C]SA1 did not show the con-
clusive decrease of VT due to large variability of VT.
On the other hand, distribution volumes of [11 C]N-me-
thyl-SSR504734 were found to decrease after pretreat-
ment with SSR504734 in a dose-dependent manner. In
the monkeys, [11 C]N-methyl-SSR504734 showed faster
receptor kinetics than [11 C]SA1, thereby providing the
equilibrium between brain and plasma, and allowing
more reliable estimation of VT values.
In the Lassen plot analysis, seven regions were used
for occupancy calculation. The thalamus seemed to be-
have differently from other regions in the plot, indicating
that the thalamus might have a different nondisplaceable
distribution volume or a different GlyT1 occupancy.
The estimated target occupancy by SSR504734 was
increased dose-dependently (Figure 9), indicating that
[11 C]N-methyl-SSR504734 could be a promising PET
ligand for occupancy studies of GlyT1 blockers.
[11 C]GSK931145 demonstrated good brain penetration
and usefulness for GlyT1 occupancy study in monkeys
[21]. However, poor test-retest results were reported in
human subjects. It might be related to a little difference
in the brain kinetics of [11 C]GSK931145 between mon-
key and human subjects. It would be important to inves-
tigate whether there is species difference in the brain
kinetics of [11 C]N-methyl-SSR504734 between monkey
and human subjects.
The present monkey PET study was performed under
anesthesia induced by ketamine and maintenaned by
sevoflurane. As ketamine is known to block NMDA
receptors as an open channel blocker, and sevoflurane is
a noncompetitive antagonist of NMDA receptor, an in-
direct interaction between these two anesthesia drugs
and glycine transporter 1 function via NMDA receptors
cannot be excluded. The use of anethesia should be
taken into account when the radioligand is considered
for further evaluation.In the present study, SSR504734 was used as a blocker.
As SSR504734 is a structurally analogous compound to
[11C]N-methyl-SSR504734, the possibility of interaction at a
nonspecific binding site was not completely excluded. If the
blocking occurs at a nonspecific binding site, estimated VND
by Lassen plot would be close to zero. Considering the esti-
mated VND by Lassen plot shown in Figure 9, the possibility
were considered to be low. To exclude the possibility com-
pletely, blocking study by compounds with different chem-
ical structure should be performed in future study.
Conclusions
In this study, [11 C]N-methyl-SSR504734 was successfully
synthesized and evaluated as a candidate PET radioli-
gand for GlyT1. [11 C]N-methyl-SSR504734 showed a re-
gional accumulation, which was consistent with previous
reports on the GlyT1 distribution. VT values were
decreased by SSR504734 in a dose-dependent manner,
suggesting specific binding. Considering these results,
[11 C]N-methyl-SSR504734 is a promising PET radioli-
gand for GlyT1. The present study warrants further PET
studies in human subjects.
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